Insulin prices in the United States have risen dramatically in recent years, yet pharmacies cannot provide a stable price for a given insulin due to factors that are not widely understood.
This commentary discusses the complex and obscure factors that drive today’s insulin prices with a discussion of the other players, besides the insulin manufacturer, who benefit from higher prices. An open discussion is critical regarding this drug and others that are essential to the lives of millions of people with diabetes. We’ll also explore whether the market introduction of biosimilar insulin will impact insulin prices.
Alan W. Carter, PharmD, Lutz Heinemann, PhD